Rigshospitalet

In 2005, Topotarget A/S entered into research collaboration with Rigshospitalet, Denmark, concerning research regarding Topotect for brain metastases. Rigshospitalet is entitled to a royalty of 4 per cent of any income which Topotarget A/S may generate through Topotect for brain metastases, up to a maximum of DKK 10 million (EUR 1.3 million).

Read more about Rigshospitalet at www.rigshospitalet.dk